{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-sclerosis/management/managing-a-relapse/","result":{"pageContext":{"chapter":{"id":"6c75c07e-8dff-5d76-9dd6-24617f774c7b","slug":"managing-a-relapse","fullItemName":"Scenario: Managing a relapse","depth":2,"htmlHeader":"<!-- begin field 9f5e79b1-b4ff-4a66-b8c3-a79b00cf1da9 --><h2>Scenario: Managing a relapse</h2><!-- end field 9f5e79b1-b4ff-4a66-b8c3-a79b00cf1da9 -->","summary":"Covers the treatment and referral of people with relapsing-remitting multiple sclerosis who are having a relapse.","htmlStringContent":"<!-- begin item f681e6b6-e298-44bf-ba87-a79b00cf1a80 --><!-- begin field ffbebf3c-d143-4662-953e-acbc0157523c --><p>From age 18 years onwards.</p><!-- end field ffbebf3c-d143-4662-953e-acbc0157523c --><!-- end item f681e6b6-e298-44bf-ba87-a79b00cf1a80 -->","topic":{"id":"d4f5f727-ed37-55a1-abb1-280e5fc9851e","topicId":"5d674db8-174e-4008-be2b-97980377bc61","topicName":"Multiple sclerosis","slug":"multiple-sclerosis","lastRevised":"Last revised in August 2020","chapters":[{"id":"5bcd2220-ea7d-5aa0-b179-870dd52d1a9d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b281488-c1a9-571c-9f76-76a0ca4f3f61","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0268dff6-e6a3-5331-9e13-7258fdfe9bdb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ac99d001-df07-5809-9d43-3d52702e71a7","slug":"changes","fullItemName":"Changes"},{"id":"0c03fe4d-4002-5f0b-a40a-ea4925270b27","slug":"update","fullItemName":"Update"}]},{"id":"6ed54162-5487-59f3-b908-b856fb8f2150","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"952c02eb-45ac-5b32-afcc-183466bb602e","slug":"goals","fullItemName":"Goals"},{"id":"4b841ec7-26b6-5463-a184-0cdf46d3b8a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6282c221-3df8-5a37-a525-cfaf733f007d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c0d0509-a813-56b1-b980-801b252d4045","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bba30032-e86d-577c-a3ca-fa9aed61784a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4744d85-2f18-554f-b380-d3bf10688018","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6c6f57ef-4211-5735-8895-4fda97d92881","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a50c93d9-2521-5417-ad53-bfb7f36d89f3","slug":"definition","fullItemName":"Definition"},{"id":"e8237fd3-792a-578e-b846-57b7431a7db8","slug":"causes","fullItemName":"Causes"},{"id":"0b182587-5c21-57f2-8398-ab8e98fcf8f6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"38108bcd-8a87-5c0b-9ae8-b9db74f1c69a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"37fb0c7f-1f18-5f13-889a-245cc60a3bee","slug":"complications","fullItemName":"Complications"},{"id":"fd2cae1b-67e8-5a36-924e-cda5c20f8a6c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7d30fb43-cd66-5aab-af72-8e461bc91727","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff701475-207f-5854-8697-487b8a3dc212","slug":"initial-presentation","fullItemName":"Initial presentation"},{"id":"fd10e131-3f32-5228-a05b-5a6267fef1b2","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"eb9fc872-e7a9-5863-bdf8-a59e3bd632f5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"7f20e1da-bbf8-57a8-a08c-b31179f8d6f2","slug":"diagnosing-a-relapse","fullItemName":"Diagnosing a relapse"}]},{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","fullItemName":"Management","slug":"management","subChapters":[{"id":"0191f771-fc85-5664-89d2-67c7d170e292","slug":"general-management","fullItemName":"Scenario: General management"},{"id":"6c75c07e-8dff-5d76-9dd6-24617f774c7b","slug":"managing-a-relapse","fullItemName":"Scenario: Managing a relapse"},{"id":"41a80c0f-66c4-59e9-b83f-74fe33a4ea7e","slug":"managing-complications","fullItemName":"Scenario: Managing complications"}]},{"id":"edace7ac-83b8-5cf1-87da-709d39382122","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"51308a75-1f5a-5ec7-87a2-42bac2d0f697","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"492510e2-a07f-5248-9cf7-ca78c4c5dd7d","slug":"baclofen","fullItemName":"Baclofen"},{"id":"4ce98dc6-eb95-55cd-b840-e2ce178eecbe","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"10cf6767-f716-53c7-abf5-fb44584b2bea","slug":"amitriptyline","fullItemName":"Amitriptyline"}]},{"id":"e3101b52-b59a-5107-b7e1-5927f9b1ac3b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d9a4c686-396a-5209-81c6-42f9e9a35598","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8534fa8f-86c0-5a20-91f4-eb030ff54379","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efebc734-6f42-5782-b6db-8c1dafca9d26","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3991ab27-1fd8-5fe7-b3dd-c9fb7fa1657e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e53280a5-7955-5f7d-86bb-6514173c53af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"eb1acd9f-4671-5653-800c-75002b20feb8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"91ad41f7-47f3-5057-a6de-8a37baf9edbc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"73d0efd4-7ec5-5e16-9583-8e1c43c98254","slug":"managing-a-relapse","fullItemName":"Managing a relapse","depth":3,"htmlHeader":"<!-- begin field dd0d2c51-78b9-40c2-ae64-a79b00cf1dae --><h3>How should I manage a person having a relapse?</h3><!-- end field dd0d2c51-78b9-40c2-ae64-a79b00cf1dae -->","summary":null,"htmlStringContent":"<!-- begin item 36201b30-5ca3-40f8-9160-a79b00cf1dae --><!-- begin field 60965be9-2b2d-425e-a5f7-a79b00cf1dae --><p><strong>If <a class=\"topic-reference internal-reference\" href=\"/topics/multiple-sclerosis/diagnosis/diagnosing-a-relapse/\">relapse</a> is suspected in a person with multiple sclerosis (MS):</strong></p><ul><li><strong>Rule out infection, particularly urinary tract and respiratory infections, and other possible conditions that can be misdiagnosed as a relapse.</strong></li><li><strong>Consider hospital admission if:</strong><ul><li>Relapse is severe.</li><li>Comorbidities such as diabetes or mental health conditions require monitoring.</li><li>Oral steroids have failed or not been tolerated.</li><li>It is difficult for the person to have their care needs met at home.</li></ul></li><li><strong>If hospital admission is not indicated, discuss management with the person's MS specialist:</strong><ul><li>Short courses of high-dose corticosteroids are often used in the treatment of relapses but are not indicated in all cases (for example some mild relapses).</li><li>The standard treatment is oral methylprednisolone 0.5 g daily for 5 days.</li><li>This should be offered as early as possible and within 14 days of onset of symptoms.</li></ul></li><li><strong>If prescription of steroids is recommended by the person’s MS specialist:</strong><ul><li>Discuss the benefits and risks, taking into account the effect of the relapse on the person’s ability to perform their usual tasks and their wellbeing. Studies suggest that steroid treatment reduces the duration of relapses by an average of 13 days, and may reduce severity.</li><li>Explain the potential complications of high-dose steroids, for example, temporary effects on mental health (such as depression, confusion, and agitation) and worsening of blood glucose control in people with diabetes.</li><li>Ideally, verbal information about steroids should be supplemented with written information.</li><li>For further information, see the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul></li><li><strong>Do not give people with MS a supply of steroids to self-administer at home for future relapses.</strong><ul><li>Doses of steroids required for treatment of relapse of MS are higher than those used for many other conditions and risk of adverse effects is increased.</li><li>Each relapse should be discussed with the specialist team as relapse frequency may influence choice of disease-modifying therapies and necessitate a change in therapy.</li></ul></li><li><strong>Discuss social care needs with the person having a relapse and their carer(s). </strong><ul><li>Refer to social services for assessment where appropriate.</li></ul></li><li><strong>Offer further information to a person having a relapse, such as:</strong><ul><li>A relapse may have short-term effects on cognitive function.</li><li>Significant recovery can be expected within 2–3 months, but improvement can continue for up to 12 months.</li><li>Some residual disability occurs following 30–50% of all relapses, and is more likely to occur if the relapse is severe.</li></ul></li></ul><!-- end field 60965be9-2b2d-425e-a5f7-a79b00cf1dae --><!-- end item 36201b30-5ca3-40f8-9160-a79b00cf1dae -->","subChapters":[{"id":"0c3e7a90-394c-58f5-b991-6546b0ab1cf9","slug":"basis-for-recommendation-c20","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ec6e5620-9ab8-4184-aacf-a79b00cf1db2 --><h4>Basis for recommendation</h4><!-- end field ec6e5620-9ab8-4184-aacf-a79b00cf1db2 -->","summary":null,"htmlStringContent":"<!-- begin item c20d9e4a-f35e-41d2-8677-a79b00cf1db2 --><!-- begin field adb36658-3c2c-4917-ada5-a79b00cf1db2 --><h5>Ruling out infection</h5><ul><li>The recommendation to rule out infection in a person suspected of having a relapse of multiple sclerosis (MS) is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].<ul><li>Expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Galea, 2015</a>] recommends that active symptomatic infection needs treatment before steroids are given but that asymptomatic dipstick positive urinary tract infection can be safely and simultaneously treated with steroids and an antibiotic.</li></ul></li></ul><h5>Hospital admission</h5><ul><li>The recommendations on when to consider hospital admission are based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li></ul><h5>Communicating promptly with the specialist MS team</h5><ul><li>The recommendation to communicate promptly with the person's specialist MS team is based on the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Galea, 2015</a>] for the following reasons:<ul><li>The specialist team will be able to help clarify the diagnosis of a relapse if there is uncertainty — diagnosis of relapse can be difficult and it is important to discriminate between relapse and fluctuations in disease progression.</li><li>It is important for the specialist team to document the time and severity of each relapse as this may affect decisions about initiation or escalation of disease-modifying therapies.</li><li>The specialist team will advise if the person should be offered steroid treatment depending on the severity of the relapse — not all relapses require steroid treatment.</li></ul></li></ul><h5>Steroid treatment</h5><ul><li>The recommendation to offer, when appropriate, oral methylprednisolone 0.5 g daily for 5 days to treat a relapse of MS is based on the NICE guideline <em>Multiple sclerosis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Galea, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>].</li><li>The NICE guideline emphasizes the importance of discussing the benefits and risks of taking high-dose steroids with the person.</li></ul><h5>Providing information about relapses</h5><ul><li>CKS acknowledges that providing information about disease is part of the normal consultation process of primary care practitioners and the information needs and requirements will become apparent during the consultation. The suggested points to raise (on cognitive function, timescale for recovery, and possible residual disability) are just some examples cited as important to raise in the NICE guideline <em>Multiple sclerosis in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Galea, 2015</a>].</li></ul><!-- end field adb36658-3c2c-4917-ada5-a79b00cf1db2 --><!-- end item c20d9e4a-f35e-41d2-8677-a79b00cf1db2 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}